Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F15%3A%230001045" target="_blank" >RIV/00064190:_____/15:#0001045 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/15:00083987 RIV/00216208:11110/15:10297713 RIV/00216208:11130/15:10297713 RIV/61989592:15110/15:33155456 RIV/00064203:_____/15:10297713

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s11523-014-0343-8" target="_blank" >http://dx.doi.org/10.1007/s11523-014-0343-8</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11523-014-0343-8" target="_blank" >10.1007/s11523-014-0343-8</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry

Popis výsledku v původním jazyce

The aim of this study was to describe the characteristics and outcomes of a large cohort of patients treated with sorafenib in clinical practice and to identify predictive factors associated with prognosis. Patient data were obtained from the national Czech registry (RenIS). Data of virtually all Czech patients receiving targeted therapies are entered into this non-interventional post-registration database. Demographics and clinical data, as well as all treatment sequences and clinical outcomes, are reported in this registry. A total of 836 patients treated with sorafenib before March 2013 were included in the analysis. Median age was 63 years and 70 % were men. Most patients had received prior treatment with cytokines, sunitinib or both. Sorafenib was the first-line treatment in 15 % of patients. Median overall survival and progression-free survival were 21.7 months and 7.5 months, respectively. Median overall survival and progression-free survival was 26.3 and 8.3 months, respectively, in patients receiving sorafenib as first-line therapy. Cox proportional models identified several parameters associated with poor outcome including time a parts per thousand currency sign1 year from diagnosis to first-line systemic treatment, performance status a parts per thousand yen2, low hemoglobin, and LDH > 1.5 times the upper limit of normal. Our data demonstrate that the outcomes of real-life patients are comparable to those enrolled in clinical trials. Prognostic factors identified in the present study were consistent with previously reported models.

Název v anglickém jazyce

Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry

Popis výsledku anglicky

The aim of this study was to describe the characteristics and outcomes of a large cohort of patients treated with sorafenib in clinical practice and to identify predictive factors associated with prognosis. Patient data were obtained from the national Czech registry (RenIS). Data of virtually all Czech patients receiving targeted therapies are entered into this non-interventional post-registration database. Demographics and clinical data, as well as all treatment sequences and clinical outcomes, are reported in this registry. A total of 836 patients treated with sorafenib before March 2013 were included in the analysis. Median age was 63 years and 70 % were men. Most patients had received prior treatment with cytokines, sunitinib or both. Sorafenib was the first-line treatment in 15 % of patients. Median overall survival and progression-free survival were 21.7 months and 7.5 months, respectively. Median overall survival and progression-free survival was 26.3 and 8.3 months, respectively, in patients receiving sorafenib as first-line therapy. Cox proportional models identified several parameters associated with poor outcome including time a parts per thousand currency sign1 year from diagnosis to first-line systemic treatment, performance status a parts per thousand yen2, low hemoglobin, and LDH > 1.5 times the upper limit of normal. Our data demonstrate that the outcomes of real-life patients are comparable to those enrolled in clinical trials. Prognostic factors identified in the present study were consistent with previously reported models.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

TARGETED ONCOLOGY

ISSN

1776-2596

e-ISSN

—

Svazek periodika

10

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

8

Strana od-do

385-392

Kód UT WoS článku

000360766400007

EID výsledku v databázi Scopus

—